NCT00168779View on ClinicalTrials.gov

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

1,185

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Hypertension
Interventions
DRUG

telmisartan 80 mg / hydrochlorothiazide 25 mg

DRUG

valsartan 160 mg / hydrochlorothiazide 25 mg

DRUG

placebo

Trial Locations (113)

Unknown

502.476.074 Boehringer Ingelheim Investigational Site, Athens

502.476.059 Boehringer Ingelheim Investigational Site, Birmingham

502.476.071 Boehringer Ingelheim Investigational Site, Birmingham

502.476.079 Boehringer Ingelheim Investigational Site, Birmingham

502.476.014 Boehringer Ingelheim Investigational Site, Huntsville

502.476.031 Boehringer Ingelheim Investigational Site, Huntsville

502.476.110 Boehringer Ingelheim Investigational Site, Huntsville

502.476.037 Boehringer Ingelheim Investigational Site, Mobile

502.476.061 Boehringer Ingelheim Investigational Site, Glendale

502.476.066 Boehringer Ingelheim Investigational Site, Carlisle

502.476.067 Boehringer Ingelheim Investigational Site, Buena Park

502.476.086 Boehringer Ingelheim Investigational Site, Encinitas

502.476.124 Boehringer Ingelheim Investigational Site, Greenbrae

502.476.005 Boehringer Ingelheim Investigational Site, Long Beach

502.476.024 Boehringer Ingelheim Investigational Site, Los Angeles

502.476.029 Boehringer Ingelheim Investigational Site, Redondo Beach

502.476.048 Boehringer Ingelheim Investigational Site, Riverside

502.476.073 Boehringer Ingelheim Investigational Site, Sacramento

502.476.087 Boehringer Ingelheim Investigational Site, San Diego

502.476.111 Boehringer Ingelheim Investigational Site, San Francisco

502.476.050 Boehringer Ingelheim Investigational Site, Santa Ana

502.476.026 Boehringer Ingelheim Investigational Site, Spring Valley

502.476.033 Boehringer Ingelheim Investigational Site, Tulsa

502.476.019 Boehringer Ingelheim Investigational Site, Boulder

502.476.101 Boehringer Ingelheim Investigational Site, Highlands Ranch

502.476.053 Boehringer Ingelheim Investigational Site, Farmington

502.476.032 Boehringer Ingelheim Investigational Site, Newark

502.476.041 Boehringer Ingelheim Investigational Site, Coral Gables

502.476.108 Boehringer Ingelheim Investigational Site, DeLand

502.476.015 Boehringer Ingelheim Investigational Site, Fort Lauderdale

502.476.044 Boehringer Ingelheim Investigational Site, Hollywood

502.476.058 FPA Clinical Research, Kissimmee

502.476.052 Boehringer Ingelheim Investigational Site, Largo

502.476.080 Boehringer Ingelheim Investigational Site, Melbourne

502.476.021 Boehringer Ingelheim Investigational Site, Panama City

502.476.012 Boehringer Ingelheim Investigational Site, Pembroke Pines

502.476.036 Boehringer Ingelheim Investigational Site, Pembroke Pines

502.476.065 Boehringer Ingelheim Investigational Site, Pembroke Pines

502.476.022 Boehringer Ingelheim Investigational Site, Atlanta

502.476.049 Boehringer Ingelheim Investigational Site, Atlanta

502.476.008 Boehringer Ingelheim Investigational Site, Conyers

502.476.075 Boehringer Ingelheim Investigational Site, Decatur

502.476.018 Boehringer Ingelheim Investigational Site, Chicago

502.476.047 Boehringer Ingelheim Investigational Site, Chicago

502.476.004 Boehringer Ingelheim Investigational Site, Peoria

502.476.062 Boehringer Ingelheim Investigational Site, Evansville

502.476.063 Boehringer Ingelheim Investigational Site, Evansville

502.476.051 Boehringer Ingelheim Investigational Site, Indianapolis

502.476.084 Boehringer Ingelheim Investigational Site, South Bend

502.476.090 Boehringer Ingelheim Investigational Site, South Bend

502.476.100 Boehringer Ingelheim Investigational Site, Newton

502.476.003 Boehringer Ingelheim Investigational Site, Wichita

502.476.038 Boehringer Ingelheim Investigational Site, Wichita

502.476.002 Boehringer Ingelheim Investigational Site, Louisville

502.476.116 Boehringer Ingelheim Investigational Site, New Orleans

502.476.035 Boehringer Ingelheim Investigational Site, Oxon Hill

502.476.010 Boehringer Ingelheim Investigational Site, Troy

502.476.028 Boehringer Ingelheim Investigational Site, Brooklyn Center

502.476.057 Boehringer Ingelheim Investigational Site, Edina

502.476.055 Boehringer Ingelheim Investigational Site, Kansas City

502.476.114 Boehringer Ingelheim Investigational Site, St Louis

502.476.112 Boehringer Ingelheim Investigational Site, Omaha

502.476.126 Boehringer Ingelheim Investigational Site, Omaha

502.476.125 Boehringer Ingelheim Investigational Site, Las Vegas

502.476.120 Boehringer Ingelheim Investigational Site, Berlin

502.476.088 Boehringer Ingelheim Investigational Site, Ship Bottom

502.476.089 Boehringer Ingelheim Investigational Site, Turnersville

502.476.068 Boehringer Ingelheim Investigational Site, Brooklyn

502.476.122 Boehringer Ingelheim Investigational Site, Hamburg

502.476.020 Boehringer Ingelheim Investigational Site, Northport

502.476.025 Boehringer Ingelheim Investigational Site, Rochester

502.476.091 Boehringer Ingelheim Investigational Site, Williamsville

502.476.046 Boehringer Ingelheim Investigational Site, Burlington

502.476.083 Boehringer Ingelheim Investigational Site, Charlotte

502.476.042 Boehringer Ingelheim Investigational Site, Raleigh

502.476.095 Boehringer Ingelheim Investigational Site, Salisbury

502.476.027 Boehringer Ingelheim Investigational Site, Winston-Salem

502.476.034 Boehringer Ingelheim Investigational Site, Cincinnati

502.476.060 Boehringer Ingelheim Investigational Site, Cincinnati

502.476.016 Boehringer Ingelheim Investigational Site, Columbus

502.476.023 Boehringer Ingelheim Investigational Site, Columbus

502.476.128 Boehringer Ingelheim Investigational Site, Columbus

502.476.064 Boehringer Ingelheim Investigational Site, Kettering

502.476.103 Boehringer Ingelheim Investigational Site, Olmsted Falls

502.476.007 Boehringer Ingelheim Investigational Site, Oklahoma City

502.476.113 Boehringer Ingelheim Investigational Site, Oklahoma City

502.476.030 Boehringer Ingelheim Investigational Site, Tulsa

502.476.104 Boehringer Ingelheim Investigational Site, Portland

502.476.109 Boehringer Ingelheim Investigational Site, Erie

502.476.094 Boehringer Ingelheim Investigational Site, Harleysville

502.476.121 Boehringer Ingelheim Investigational Site, Penndel

502.476.072 Boehringer Ingelheim Investigational Site, Philadelphia

502.476.076 Boehringer Ingelheim Investigational Site, Springfield

502.476.013 Boehringer Ingelheim Investigational Site, East Providence

502.476.085 Boehringer Ingelheim Investigational Site, Cordova

502.476.096 Boehringer Ingelheim Investigational Site, Jackson

502.476.081 Boehringer Ingelheim Investigational Site, New Tazewell

502.476.082 Boehringer Ingelheim Investigational Site, Selmer

502.476.039 Boehringer Ingelheim Investigational Site, Carrollton

502.476.056 Boehringer Ingelheim Investigational Site, Dallas

502.476.069 Boehringer Ingelheim Investigational Site, Dallas

502.476.107 Boehringer Ingelheim Investigational Site, Dallas

502.476.070 Boehringer Ingelheim Investigational Site, Killeen

502.476.001 Boehringer Ingelheim Investigational Site, Bountiful

502.476.006 Boehringer Ingelheim Investigational Site, Salt Lake City

502.476.017 Boehringer Ingelheim Investigational Site, Salt Lake City

502.476.097 Boehringer Ingelheim Investigational Site, Sandy City

502.476.098 Boehringer Ingelheim Investigational Site, Sandy City

502.476.011 Boehringer Ingelheim Investigational Site, Falls Church

502.476.093 Boehringer Ingelheim Investigational Site, Norfolk

502.476.078 Boehringer Ingelheim Investigational Site, Tacoma

502.476.106 Boehringer Ingelheim Investigational Site, Menomonee Falls

502.476.105 Boehringer Ingelheim Investigational Site, Milwaukee

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00168779 - Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension | Biotech Hunter | Biotech Hunter